Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhC1INH for acute hereditary angioedema attacks
2011-000049-19Phase 3Completed
- Sponsor
- Pharming Group
- Start
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of conestat alfa in hereditary angioedema (HAE) (3 arms), sponsored by Pharming Group. Primary endpoints: Time to beginning of relief and Sensitivity analyses for time to beginning of relief. Started Feb 2011; status: completed.
02
Drugs
conestat alfa
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2011-000049-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000049-19.